SCHEMBL12323563

SCHEMBL12323563

COc1ccc(C[C@@H](C)NC(C)=O)cc1S(N)(=O)=O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 9/20 0.58
▸ ADRA1D P25100 6/20 0.56
▸ ADRA1A P35348 6/20 0.56
▸ ADRA1B P35368 6/20 0.56
▸ ADRB2 P07550 1/20 0.56
▸ ADRB1 P08588 1/20 0.56
▸ HTR1A P08908 1/20 0.56
▸ ADRA2A P08913 1/20 0.56
▸ DRD2 P14416 1/20 0.56
▸ ADRA2B P18089 1/20 0.56
▸ ADRA2C P18825 1/20 0.56
▸ HTR2A P28223 1/20 0.56
▸ HTR7 P34969 1/20 0.56
▸ OPRM1 P35372 1/20 0.56
▸ DRD3 P35462 1/20 0.56
▸ HTR2B P41595 1/20 0.56
▸ KCNH2 Q12809 1/20 0.56
▸ PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14370514 1.00 ACACB (0.58) ACACBADRA1DADRA1AADRA1BADRB2
SCHEMBL5052802 0.87 ADRA1D (0.53) ACACBADRA1DADRA1AADRA1BADRB2
SCHEMBL5052805 0.87 ADRA1D (0.53) ACACBADRA1DADRA1AADRA1BADRB2
SCHEMBL5059309 0.87 ADRA1D (0.56) ACACBADRA1DADRA1AADRA1BADRB2
SCHEMBL14300657 0.87 ADRA1D (0.53) ACACBADRA1DADRA1AADRA1BADRB2
SCHEMBL5059304 0.87 ADRA1D (0.56) ACACBADRA1DADRA1AADRA1BADRB2
SCHEMBL1412301 0.86 ADRA1D (0.59) ACACBADRA1DADRA1AADRA1BADRB2
SCHEMBL1412297 0.86 ADRA1D (0.59) ACACBADRA1DADRA1AADRA1BADRB2
SCHEMBL13067728 0.84 ADRA1D (0.60) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL4356427 0.83 ADRA1D (0.45) ACACBADRA1DADRA1AADRA1BADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017803-B2 Process for the preparation of tamsulosin and intermediates thereof HOVIONE INTER LTD. (CH) 2011-09-13 — — US disclosed
EP-1734036-B1 Process for preparation of tamsulosin and its derivatives WELL BEING BIOCHEMICAL CORP (TW) 2011-08-31 — — EP disclosed
EP-1996544-B1 A METHOD OF PREPARATION OF (R)-(-)-5(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE ZENTIVA KS (CZ) 2010-11-10 — — EP disclosed
US-7638649-B2 Method of preparation of (R)-(−)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide ZENTIVA, K.S. (CZ) 2009-12-29 — — US disclosed
US-20090234154-A1 Process for the preparation of tamsulosin and intermediates thereof HOVIONE INTER LTD. 2009-09-17 — — US disclosed
US-20080319225-A1 Method of Preparation of (R)-(-)-5(2-Aminopropyl)-2-Methoxybenzenesulfonamide ZENTIVA, A.S. (CZ) 2008-12-25 — — US disclosed
US-7282606-B2 Process for preparation of tamsulosin and its aralkylamine derivatives WELL-BEING BIOCHEMICAL CORP. (TW) 2007-10-16 — — US disclosed
US-20070015939-A1 Process for preparation of tamsulosin and its aralkylamine derivatives WELL-BEING BIOCHEMICAL CORP (TW) 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234154-A1 Process for the preparation of tamsulosin and intermediates thereof AVPR2, AVPR1B, TACR2 ACACB 3833/4885ADRA1D 31/4885ADRA1A 57/4885
US-20080319225-A1 Method of Preparation of (R)-(-)-5(2-Aminopropyl)-2-Methoxybenzenesulfonamide NPSR1, TPSAB1, TPSB2 ACACB 4272/4885ADRA1D 22/4885ADRA1A 45/4885
US-20070015939-A1 Process for preparation of tamsulosin and its aralkylamine derivatives ADRB1, ADRA2B, ADRA2A ACACB 2883/4885ADRA1D 7/4885ADRA1A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback